Scarica l'app Stockscreener
0.43
5.43%
-0.0247
Dopo l'orario di chiusura:
.46
0.03
+6.98%
Precedente Chiudi:
$0.4547
Aprire:
$0.4548
Volume 24 ore:
762.15K
Relative Volume:
0.29
Capitalizzazione di mercato:
$17.89M
Reddito:
-
Utile/perdita netta:
$-74.56M
Rapporto P/E:
-0.2348
EPS:
-1.8316
Flusso di cassa netto:
$-60.27M
1 W Prestazione:
+5.86%
1M Prestazione:
+31.86%
6M Prestazione:
-50.87%
1 anno Prestazione:
-66.92%
Intervallo 1D:
$0.43
$0.4661
Intervallo di 1 settimana:
$0.386
$0.495
Portata 52W:
$0.2201
$1.54
Rallybio Corp Stock (RLYB) Company Profile
Nome
Rallybio Corp
Settore
Industria
Telefono
203- 859-3820
Indirizzo
234 CHURCH STREET, NEW HAVEN
Confronta RLYB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RLYB
Rallybio Corp
|
0.43 | 16.90M | 0 | -74.56M | -60.27M | -1.8316 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.81 | 120.40B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.52 | 61.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.53 | 41.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
564.59 | 34.29B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.55 | 27.09B | 3.81B | -644.79M | -669.77M | -6.24 |
Rallybio Corp Stock (RLYB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-09 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-05-15 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-07 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-17 | Iniziato | H.C. Wainwright | Buy |
| 2023-04-10 | Iniziato | Wedbush | Outperform |
| 2022-12-09 | Iniziato | JP Morgan | Overweight |
| 2022-02-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-08-23 | Iniziato | Cowen | Outperform |
| 2021-08-23 | Iniziato | Evercore ISI | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
Mostra tutto
Rallybio Corp Borsa (RLYB) Ultime notizie
Rallybio Corporation Stock Analysis and ForecastMarket-beating performance - Jammu Links News
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock - MSN
Deal Watch: Debiopharm Takes On Precision Oncology Drug From Repare Collab - insights.citeline.com
What makes Rallybio Corporation stock price move sharplyFree Best Performing Stock Alerts - Newser
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug - MSN
How Rallybio Corporation stock performs during market volatilityCarefully Curated High Return Stocks - Newser
Why Rallybio Corporation stock attracts strong analyst attentionFree Access to Investment Community - Newser
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate - simplywall.st
Recursion Pharmaceuticals (RXRX) Rallies 8.7% on Hypophosphatasia - Insider Monkey
RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program - TradingView
Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M - Yahoo Finance
Rallybio sells REV102 programme to Recursion for up to $25m - Pharmaceutical Business review -
Rallybio Drops 9.98% Despite Q1 Progress, Recursion Deal - AInvest
Rallybio sells HPP treatment program to Recursion for up to $25 million By Investing.com - Investing.com South Africa
Biotech Stocks Climb With Recursion's Bold Move Forward - Finimize
Recursion Pharmaceuticals stock soars after acquiring HPP treatment from Rallybio - Investing.com India
Recursion Pharmaceuticals Rises With Rallybio Acquisition Move - Finimize
Recursion, Rallybio Shares Rise After Deal on Joint Hypophosphatasia Candidate - MarketScreener
Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals - citybiz
RallyBio - Hartford Business Journal
Rallybio sells interest in drug program in deal worth up to $25M - Hartford Business Journal
Why Is Microcap Rallybio Stock Trading Higher On Tuesday? - Benzinga
Rallybio Stock (RLYB) Rockets 25% on a Recursion Pharmaceuticals Agreement - TipRanks
Rallybio shifts gears, cashing out of Recursion pact to extend runway - Fierce Biotech
Rallybio stock climbs on deal with Recursion (RLYB:NASDAQ) - Seeking Alpha
Rallybio sells interest in REV102 program to Recursion Pharmaceuticals - grafa.com
Rallybio Sells REV102 Program to Recursion Pharmaceuticals - TipRanks
Rallybio sells HPP treatment program to Recursion for up to $25 million - Investing.com
ImmunoPrecise Strengthens Board with 30-Year Biotech Veteran Jon Lieber from Rallybio - Stock Titan
Rallybio Finalizes Employment Agreement with CMO - TipRanks
Rallybio’s FNAIT Study: A Closer Look at HPA-1a Alloimmunization - TipRanks
Rallybio’s Phase 2 Study on RLYB212: A Potential Game-Changer for Pregnant Women at Risk - TipRanks
Affibody’s licensee Rallybio Announces Initiation of Dosing with RLYB116 in Phase 1 Confirmatory PK/PD Study - TradingView
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 By Investing.com - Investing.com South Africa
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study - BioSpace
Rallybio begins dosing in phase 1 study of C5 inhibitor RLYB116 - Investing.com India
Rallybio Initiates Dosing In RLYB116 Phase 1 Confirmatory Study - MarketScreener
Rallybio's $5B Market Opportunity: New Phase 1 Trial Targets Two Untreated Rare Blood Disorders - Stock Titan
RLYBRallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial - mx.advfn.com
Connecticut biotech shows resilience amid recent layoffs at Arvinas, RallyBio - Trumbull Times
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook By Investing.com - Investing.com Canada
Rallybio’s SWOT analysis: C5 inhibitor focus shifts stock outlook - Investing.com
Rallybio shareholders elect directors, ratify auditor By Investing.com - Investing.com Nigeria
Rallybio shareholders elect directors, ratify auditor - Investing.com
Rallybio Elects New Directors at Shareholder Meeting - TipRanks
Rallybio Corp Azioni (RLYB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.59%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):